{"id":"NCT00395512","sponsor":"Takeda","briefTitle":"Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","officialTitle":"A Multicenter, Double-Blind Study to Determine the Efficacy and Safety of SYR-322 Plus Pioglitazone HCl (Actos®), SYR-322 Alone or Pioglitazone HCl Alone in Subjects With Type 2 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2006-11-03","resultsPosted":"2013-03-27","lastUpdate":"2013-03-27"},"enrollment":655,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Alogliptin","otherNames":["SYR-322"]},{"type":"DRUG","name":"Pioglitazone","otherNames":["Actos","AD4833"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Alogliptin 25 mg QD","type":"EXPERIMENTAL"},{"label":"Pioglitazone 30 mg QD","type":"ACTIVE_COMPARATOR"},{"label":"Alogliptin 25 mg QD+ Pioglitazone 30 mg QD","type":"EXPERIMENTAL"},{"label":"Alogliptin 12.5 mg QD + Pioglitazone 30 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the combination of alogliptin, once daily (QD), and pioglitazone in patients with type 2 diabetes mellitus who are inadequately controlled with diet and exercise alone.","primaryOutcome":{"measure":"Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)","timeFrame":"Baseline and Week 26","effectByArm":[{"arm":"Alogliptin 25 mg","deltaMin":-0.96,"sd":0.081},{"arm":"Pioglitazone 30 mg","deltaMin":-1.15,"sd":0.083},{"arm":"Alogliptin 25 mg + Pioglitazone 30 mg","deltaMin":-1.71,"sd":0.081},{"arm":"Alogliptin 12.5 mg + Pioglitazone 30 mg","deltaMin":-1.56,"sd":0.081}],"pValues":[{"comp":"OG001 vs OG002","p":"<0.001"},{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG003","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":22},"locations":{"siteCount":161,"countries":["United States","Argentina","Australia","Brazil","Bulgaria","Chile","Croatia","Estonia","Guatemala","Hungary","India","Israel","Latvia","Lithuania","Mexico","New Zealand","Poland","Romania","Russia","Serbia","Slovakia","South Africa","Ukraine"]},"refs":{"pmids":["20724648"],"seeAlso":["http://general.takedapharm.com/content/file/pi.pdf?applicationcode=ab2d7112-8eb3-465a-8fda-35018a9eafb0&fileTypeCode=ACTOSPI"]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":164},"commonTop":["Headache","Urinary tract infection","Back pain","Oedema peripheral"]}}